Theravance Biopharma Inc (OQ:TBPH)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: UGLAND HOUSE, SOUTH CHURCH STREET
GEORGE TOWN KY1-1104
Tel: N/A
Website: https://www.theravance.com
IR: See website
<
Key People
Rick E. Winningham
Chairman of the Board, Chief Executive Officer
Aziz Sawaf
Chief Financial Officer, Senior Vice President
Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Rhonda F. Farnum
Senior Vice President - Commercial and Medical Affairs, Chief Business Officer
   
Business Overview
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.
Financial Overview
For the fiscal year ended 31 December 2023, Theravance Biopharma Inc revenues increased 12% to $57.4M. Net loss before extraordinary items decreased 41% to $55.2M. Revenues reflect Europe segment increase of less than 1% to $223K. Lower net loss reflects Research and development - bal decrease of 36% to $32.6M (expense), Restructuring and related expenses decrease of 79% to $2.7M (expense).
Employees: 99 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $331.54M as of Dec 31, 2023
Annual revenue (TTM): $57.42M as of Dec 31, 2023
EBITDA (TTM): -$51.29M as of Dec 31, 2023
Net annual income (TTM): -$55.19M as of Dec 31, 2023
Free cash flow (TTM): -$29.49M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 48,164,708 as of Feb 23, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.